AKT1 and pachyonychia congenita: There are several studies have examined this before; for instance, targeting the PI3K-Akt-mTOR pathway in PC as a clinical treatment [67-69], PI3K pathway is dominant over androgen receptor signaling in PC [70], and activation of PI3K pathway promotes PC cell invasion [71].